HOYA Vision Care Presents Breakthrough 6-Month MiYOSMART iQ Clinical Evidence at Asia-Pacific Academy of Ophthalmology Congress 2026

• At 6 months, children aged 4-12 wearing MiYOSMART iQ spectacle lenses showed no myopia progression on average, with minimal eye growth.^1,2
• MiYOSMART iQ spectacle lenses are twice as effective as MiYOSMART spectacle lenses in controlling axial elongation and myopia progression, based on clinical evidence.²

HONG KONG, Feb. 06, 2026 – HOYA Vision Care today at the 41^st Asia-Pacific Academy of Ophthalmology Congress in Hong Kong (February 05–08, 2026) announced interim 6-month clinical evidence from a randomized controlled clinical trial evaluating the safety and efficacy of MiYOSMART iQ spectacle lenses, the company’s novel myopia control solution that builds on its clinically proven Defocus Incorporated Multiple Segments (D.I.M.S.) Technology, now with Triple Enhanced Design (DIMS TED), in children aged 4–12 with progressive myopia.²

“These are the most impressive myopia control results seen so far with D.I.M.S Technology based spectacle lenses,” said Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs, HOYA Vision Care. “The conversation has now moved beyond slowing down myopia progression; with the compelling clinical evidence behind MiYOSMART iQ, we are entering a new era of myopia control – where no myopia progression on average could be reached.”

MiYOSMART iQ advances HOYA’s proprietary D.I.M.S. Technology with Triple Enhanced Design, featuring three design enhancements that drive higher effectiveness compared to the previous MiYOSMART spectacle lenses. A smaller clear central zone, with defocus segments closer to the spectacle lens center, intends to continuously activate the near-peripheral retina – identified as the region most responsive to myopic defocus. Higher defocus power enables a stronger myopic defocus signal, and an extended treatment zone with more defocus segments ensures extensive coverage of the child’s peripheral visual field, even for larger frames.^3,4

"With childhood myopia on the rise globally, MiYOSMART iQ represents the culmination of over a decade of HOYA innovation and research dedicated to addressing this challenge,” said John Goltermann Lassen, CEO, HOYA Vision Care. “With DIMS TED, we’ve developed our most advanced myopia control solution yet – elevating the standard of care in myopic children’s vision, by ushering in a new age in which there is no myopia progression on average. What’s more, myopic children and their families can be assured that MiYOSMART iQ spectacle lenses are crafted with aesthetics in mind and look just like standard SV spectacle lenses. This thoughtful innovation reflects our commitment to protecting children's vision health and to providing Eye Care Professionals with the scientific foundation they need to deliver the highest standard of pediatric care."

MiYOSMART iQ is currently available in major eye hospitals across China, with plans to continue the roll-out throughout 2026. MiYOSMART iQ will be sold alongside HOYA Vision Care’s well-established MiYOSMART spectacle lenses. Since its launch in 2018, more than 13 million MiYOSMART spectacle lenses have already been purchased by parents in over 50 countries worldwide.⁵ The addition of MiYOSMART iQ to the MiYOSMART range represents a new era in myopia control. HOYA Vision Care remains committed to evolving treatment solutions and working closely with Eye Care Professionals and parents, to help expand access to effective, innovative care for children with myopia.

For more information about MiYOSMART iQ, please contact your local HOYA Vision Care representative or visit: hoyavision.com.

Disclaimer: These findings are based on interim data and should not be interpreted as long-term outcomes.

Product Disclaimer: MiYOSMART and MiYOSMART iQ spectacle lenses have not been approved for use in the management of myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.

Footnotes

1. HOYA data on file. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Triple Enhanced Design Spectacle Lenses: 6-month results. 11/2025. Peer-reviewed publication will follow.
2. Tse DYY, et al. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Triple Enhanced Design Spectacle Lenses. The 41st Asia-Pacific Academy of Ophthalmology Congress, February 5–8, 2026. Abstract 205567. https://2026.apaophth.org/abstract/?code=205567 (Accessed: February 2026)
3. Swiatczak B, et al. Retinal "sweet spot" for myopia treatment. Sci Rep. 2024;14:26773.
4. Smith IEL, et al. Eccentricity-dependent effects of simultaneous competing defocus on emmetropization in infant rhesus monkeys. Vision Res. 2020;177:32-40.
5. Based on the number of MiYOSMART spectacle lenses sold and the number of countries selling MiYOSMART spectacle lenses according to HOYA’s sales data on file as of January 26.